ROS-responsive Hierarchical Targeting Vehicle-Free Nanodrugs for Three-Pronged Parkinson’s Disease Therapy

Zhongxiong Fan,Hao Jin,Xiaofeng Tan,Ying Li,Dao Shi,Qiuli Wang,Jiahao Meng,Wenjun Li,Caixia Chen,Lu Peng,Zhenqing Hou,Jingwen Li,Xin Jin,Lichao Yang

DOI: https://doi.org/10.1016/j.cej.2023.143245

IF: 15.1

2023-01-01

Chemical Engineering Journal

Abstract:Although nanodrugs have shown striking potential toward Parkinson's Disease (PD) therapy, lack of brain targeting and on-demand drug release, as well as low drug payload seriously impede various nanodrugs further applied in PD. Here, motivated via the fact that the smart self-targeting nanodrugs can enhance blood-brain barrier (BBB) penetration, brain-targeting efficency, and cellular delivery, we have constructed a reactive oxygen species (ROS)-responsive hierarchical targeting vehicle-free nanodrugs for spatiotemporally selective PD therapy. Such nanodrugs are constructed via self-assembly of rasagiline mesylate (RM) and dopamine (DA)-thioketalDA dimer. The obtained nanodrugs with high drug payload, excellent physiological stability, and suitable diamter can specifically cross BBB and then internalize into endothelial and neuronal cells through DA receptormediated transcytosis. After that, nanodrugs can be disassembled under stimuli of the PD-endogenous ROS, thereby resulting in simultaneous spatiotemporal on-demand burst release of DA and RM. Moreover, our new findings show that DA and RM released from nanodrugs possess an outstanding three-pronged therapeutic effect on PD by inhibiting alpha-synuclein (alpha-syn) aggregation and neuroinflammation and enhancing DA neurons survival. In a word, we propose a central nervous system disease microenvironment-responsive vehicle-free hierarchical targeting therapeutic strategy for PD therapy.